@article{article, title  = {{Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial}},

 publisher = {{Elsevier BV}},

 url = {{http://dx.doi.org/10.1016/s1470-2045(23)00460-6 }},

 year = {{2023}},

 month = {{11}},

 author = {{Velikova G and Morden JP and Haviland JS and Emery C and Barrett-Lee P and Earl H and Bloomfield D and Brunt AM and Canney P and Coleman R and Verrill M et al}},

 doi = {{10.1016/s1470-2045(23)00460-6}},

 volume = {{24}},

 journal = {{The Lancet Oncology}},

 issue = {{12}},

 pages = {{1359-1374}},

 note = {{Accessed on 2025/10/10}}}